Welcome to our dedicated page for Vyome Holdings news (Ticker: HIND), a resource for investors and traders seeking the latest updates and insights on Vyome Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vyome Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vyome Holdings's position in the market.
Vyome Holdings (NASDAQ:HIND) has announced the acquisition of Oculo, Inc., an MIT AI spinout, and launched a new business unit focused on using AI to combat inflammation. The company aims to develop an AI psychiatrist trained on US and India data to diagnose and treat systemic inflammation by targeting behavioral drivers and biomarkers.
A newly-formed AI subcommittee of MIT alumni will oversee the initiative, which aims to establish a novel therapeutic category combining mental health, psychoneuroimmunology, and digital health. The company confirms it remains fully funded through 2026 to advance its core biotech assets, with the digital therapeutics market potential estimated at over $100B in the next decade.
Vyome Holdings (NASDAQ: HIND) has strengthened its leadership team with two significant appointments. Dr. Richard Fahrner, with over 25 years of drug development experience and involvement in 17 approved medicines, joins as Chief Technology Officer. Dr. Tamara Agajanov, bringing nearly 30 years of clinical operations expertise, takes the role of Senior Vice President – Clinical Development.
The company is currently conducting a Phase 2 study in malignant fungating wounds (MFW), representing a potential multi-billion dollar market opportunity. Topline results are expected by October 2025. The appointments come at a crucial time as Vyome prepares for pivotal trial studies, with interim Phase 2 results in MFW described as "very encouraging."
Vyome Holdings (NASDAQ:HIND) has announced positive interim results from its Phase 2 proof-of-concept study of VT-1953 topical gel for treating malignant fungating wounds (MFW). The study demonstrated statistically significant improvements in the primary endpoint of reducing wound-associated malodor (P<0.001), as well as secondary endpoints including lesion pain reduction and quality of life improvement.
MFW affects 5-14% of advanced cancer patients, with an estimated 650,000 patients in the US and 10 million globally. The company estimates a $1 billion market opportunity in the United States alone. VT-1953 has shown good tolerability in over 500 patients, with no clinically significant adverse effects reported. Vyome plans to interact with the FDA in early 2026, with full results expected in October 2026.
Vyome Holdings (NASDAQ:HIND), a clinical-stage healthcare holding company, has signed a non-binding Memorandum of Understanding (MoU) with Embryyo Technologies, an Indian medical device innovation studio. The partnership aims to explore opportunities in the AI-enabled medical device market.
The collaboration combines Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to develop smart medical devices for disease management and treatment. Embryyo's portfolio includes developments in interventional oncology, surgery, wearables, and drug delivery. As part of the initiative, both companies will host a global AI-enabled medical device innovation forum focusing on the US-India corridor.
Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced a strategic review of its 70% controlling stake in Livechain Inc. (OTCID: LICH). The Board of Directors will spend the next month evaluating various options for Livechain.
The strategic alternatives under consideration include launching a new business, forming a crypto treasury, pursuing a merger, or selling the asset. Vyome initially acquired its controlling interest in LICH in 2021 with plans to establish a viable publicly traded business on the OTC market. With Vyome now trading on Nasdaq, the company is exploring new opportunities for its Livechain investment.
Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare company, marks its first day of trading on Nasdaq by ringing the opening bell, coinciding with India's 79th Independence Day. The company focuses on developing treatments for immuno-inflammatory and rare diseases in the US and global markets.
The company emphasizes its debt-free status and shareholder-aligned board structure. Vyome's pipeline targets the $100 billion immuno-inflammatory market, leveraging talent from both the US and India. The leadership team includes Chairman Krishna Gupta, Founder Shiladitya Sengupta (Associate Professor at Harvard Medical School), and Co-founder and CEO Venkat Nelabhotla.
Vyome Therapeutics has completed its previously announced merger with ReShape Lifesciences (Nasdaq: RSLS). The combined entity, to be known as Vyome Holdings, will begin trading on Nasdaq under the new ticker symbol "HIND" on August 15, 2025. Vyome is a clinical-stage healthcare company focused on developing treatments for immuno-inflammatory and rare diseases in US and global markets.
FAQ
What is the current stock price of Vyome Holdings (HIND)?
What is the market cap of Vyome Holdings (HIND)?
